ES2180446A1 - Empleo de derivados de acidos 2,5-dihidroxibencenosulfonicos en la elaboracion de un medicamento para potenciar el efecto de otros farmacos en el tratamiento de la disfuncion erectil. - Google Patents

Empleo de derivados de acidos 2,5-dihidroxibencenosulfonicos en la elaboracion de un medicamento para potenciar el efecto de otros farmacos en el tratamiento de la disfuncion erectil.

Info

Publication number
ES2180446A1
ES2180446A1 ES200101535A ES200101535A ES2180446A1 ES 2180446 A1 ES2180446 A1 ES 2180446A1 ES 200101535 A ES200101535 A ES 200101535A ES 200101535 A ES200101535 A ES 200101535A ES 2180446 A1 ES2180446 A1 ES 2180446A1
Authority
ES
Spain
Prior art keywords
agents
effect
iia
relaxation
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200101535A
Other languages
English (en)
Other versions
ES2180446B1 (es
Inventor
Jose Esteve-Soler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Laboratorios del Dr Esteve SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200101535A priority Critical patent/ES2180446B1/es
Application filed by Laboratorios del Dr Esteve SA filed Critical Laboratorios del Dr Esteve SA
Priority to AT02745439T priority patent/ATE419012T1/de
Priority to PL02367766A priority patent/PL367766A1/xx
Priority to JP2003510106A priority patent/JP2005501031A/ja
Priority to PCT/ES2002/000325 priority patent/WO2003004097A1/es
Priority to ARP020102472A priority patent/AR036124A1/es
Priority to CA002453572A priority patent/CA2453572A1/en
Priority to BR0211315-5A priority patent/BR0211315A/pt
Priority to DE60230629T priority patent/DE60230629D1/de
Priority to HU0400924A priority patent/HUP0400924A3/hu
Priority to US10/482,457 priority patent/US20040143010A1/en
Priority to ES02745439T priority patent/ES2318023T3/es
Priority to EP02745439A priority patent/EP1413332B1/en
Priority to MXPA04000007A priority patent/MXPA04000007A/es
Publication of ES2180446A1 publication Critical patent/ES2180446A1/es
Priority to NO20040007A priority patent/NO20040007L/no
Application granted granted Critical
Publication of ES2180446B1 publication Critical patent/ES2180446B1/es
Priority to US11/641,269 priority patent/US20070197543A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Empleo de derivados de ácidos 2,5-dihidroxibenceno-sulfónicos en la elaboración de un medicamento para potenciar el efecto de otros fármacos en el tratamiento de la disfunción eréctil. La presente invención se refiere al empleo de derivados de ácidos 2,5-dihidroxibencenosulfónicos de fórmula general (I), en la elaboración de medicamentos útiles en terapéutica para potenciar los efectos de los inhibidores de la fosfodiesterasa-5 incluyendo sildenafilo, vardenafilo y IC-351, de apomorfina, de los donadores de óxido nítrico incluyendo nitrato de amilo, nitroglicerina, nitroprusiato, nitrosotioles y nicorandilo, de los compuestos que aumentan el nivel de GMP cíclico en el tejido peneano y de otros compuestos destinados a promover la erección del pene en el hombre.
ES200101535A 2001-07-02 2001-07-02 Empleo de derivados de acidos 2,5-dihidroxibencenosulfonicos en la elaboracion de un medicamento para potenciar el efecto de otros farmacos en el tratamiento de la disfuncion erectil. Expired - Fee Related ES2180446B1 (es)

Priority Applications (16)

Application Number Priority Date Filing Date Title
ES200101535A ES2180446B1 (es) 2001-07-02 2001-07-02 Empleo de derivados de acidos 2,5-dihidroxibencenosulfonicos en la elaboracion de un medicamento para potenciar el efecto de otros farmacos en el tratamiento de la disfuncion erectil.
US10/482,457 US20040143010A1 (en) 2001-07-02 2002-07-01 Use of derivatives of 2, 5-dihydroxybenzenesulphonic acid derivatives in the production of a medication used to potentiate the effect of other drugs in the treatment of erectile dysfunction
JP2003510106A JP2005501031A (ja) 2001-07-02 2002-07-01 勃起障害の治療における他の薬物の効果を増強するために用いる医薬の生産における２，５−ジヒドロキシベンゼンスルホン酸誘導体の使用
PCT/ES2002/000325 WO2003004097A1 (es) 2001-07-02 2002-07-01 Empleo de derivados de ácidos 2,5-dihidroxibencenosulfónicos en la elaboración de un medicamento para potenciar el efecto de otros fármacos en el tratamiento de la disfunción eréctil
ARP020102472A AR036124A1 (es) 2001-07-02 2002-07-01 Empleo de derivados de acidos 2,5-dihidroxibencenosulfonicos en la elaboracion de un medicamento para potenciar el efecto de otros farmacos en el tratamiento de la disfuncion erectil
CA002453572A CA2453572A1 (en) 2001-07-02 2002-07-01 The use of derivatives of 2,5-dihydroxybenxenesulphonic acids in the elaboration of a medicinal product to enhance the effect of other drugs used for the treatment of erectile disfunction
BR0211315-5A BR0211315A (pt) 2001-07-02 2002-07-01 Uso de derivados de ácido 2,5-diidroxibenzeno-sulfÈnicos na elaboração de um produto medicinal para aumentar o efeito de outros medicamentos utilizados no tratamento de disfunção erétil
DE60230629T DE60230629D1 (de) 2001-07-02 2002-07-01 Verwendung von 2,5-dihydroxybenzolsulfonsäure-derivaten bei der herstellung eines medikaments zur verstärkung der wirkung anderer arzneimittel zur behandlung der erektilen dysfunktion
AT02745439T ATE419012T1 (de) 2001-07-02 2002-07-01 Verwendung von 2,5-dihydroxybenzolsulfonsäure- derivaten bei der herstellung eines medikaments zur verstärkung der wirkung anderer arzneimittel zur behandlung der erektilen dysfunktion
PL02367766A PL367766A1 (en) 2001-07-02 2002-07-01 Use of 2,5-dihydroxybenzenesulphonic acid derivatives in the production of a medicament used to potentiate the effect of other drugs in the treatment of erectile dysfunction
ES02745439T ES2318023T3 (es) 2001-07-02 2002-07-01 Uso de derivados de acidos 2,5-dihidroxibenceno-sulfonicos en la elaboracion de un medicamento para potenciar el efecto de otros farmacos en el tratamiento de la disfuncion erectil.
EP02745439A EP1413332B1 (en) 2001-07-02 2002-07-01 Use of 2,5-dihydroxybenzenesulphonic acid derivatives in the production of a medicament used to potentiate the effect of other drugs in the treatment of erectile dysfunction
MXPA04000007A MXPA04000007A (es) 2001-07-02 2002-07-01 Empleo de derivados de acidos 2,5-dihicroxibenceno-sulfonicos en la elaboracion de un medicamento para potenciar el efecto de otros farmacos en el tratamiento de la disfuncion erectil.
HU0400924A HUP0400924A3 (en) 2001-07-02 2002-07-01 Use of 2,5-dihydroxybenzenesulfphonic acid derivatives in the production of a medicament used to potentiate the effect of other drugs in the treatment of erectile dysfunction
NO20040007A NO20040007L (no) 2001-07-02 2004-01-02 Anvendelse av 2,5-dihydroksybenzensulfonsyrederivater ved fremstilling av medikament for a fremme effekten av andre medikamenter ved behandling av erektil dysfunksjon
US11/641,269 US20070197543A1 (en) 2001-07-02 2006-12-19 Use of derivatives of 2, 5-dihydroxyb enzene-sulphonic acids in the elaboration of a medicinal product to enhance the effect of other drugs used for the treatment of erectile dysfunction

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200101535A ES2180446B1 (es) 2001-07-02 2001-07-02 Empleo de derivados de acidos 2,5-dihidroxibencenosulfonicos en la elaboracion de un medicamento para potenciar el efecto de otros farmacos en el tratamiento de la disfuncion erectil.

Publications (2)

Publication Number Publication Date
ES2180446A1 true ES2180446A1 (es) 2003-02-01
ES2180446B1 ES2180446B1 (es) 2004-01-16

Family

ID=8498259

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200101535A Expired - Fee Related ES2180446B1 (es) 2001-07-02 2001-07-02 Empleo de derivados de acidos 2,5-dihidroxibencenosulfonicos en la elaboracion de un medicamento para potenciar el efecto de otros farmacos en el tratamiento de la disfuncion erectil.
ES02745439T Expired - Lifetime ES2318023T3 (es) 2001-07-02 2002-07-01 Uso de derivados de acidos 2,5-dihidroxibenceno-sulfonicos en la elaboracion de un medicamento para potenciar el efecto de otros farmacos en el tratamiento de la disfuncion erectil.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES02745439T Expired - Lifetime ES2318023T3 (es) 2001-07-02 2002-07-01 Uso de derivados de acidos 2,5-dihidroxibenceno-sulfonicos en la elaboracion de un medicamento para potenciar el efecto de otros farmacos en el tratamiento de la disfuncion erectil.

Country Status (14)

Country Link
US (2) US20040143010A1 (es)
EP (1) EP1413332B1 (es)
JP (1) JP2005501031A (es)
AR (1) AR036124A1 (es)
AT (1) ATE419012T1 (es)
BR (1) BR0211315A (es)
CA (1) CA2453572A1 (es)
DE (1) DE60230629D1 (es)
ES (2) ES2180446B1 (es)
HU (1) HUP0400924A3 (es)
MX (1) MXPA04000007A (es)
NO (1) NO20040007L (es)
PL (1) PL367766A1 (es)
WO (1) WO2003004097A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2311427A1 (es) * 2004-12-30 2009-02-01 Laboratorios Del Dr. Esteve, S.A. Composicion farmaceutica que comprende un compuesto 2,5-dihidroxibencenosulfonico, un modulador de canales de iones potasio y un inhibidor de la fosfodiesterasa tipo 5.

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2208123A1 (es) * 2002-11-29 2004-06-01 Laboratorios Del Dr. Esteve, S.A. Uso de los compuestos 2,5-dihidroxibencenosulfonicos para la fabricacion de un medicamento.
ES2222831B2 (es) * 2003-07-30 2006-02-16 Laboratorios Del Dr. Esteve, S.A. Combinacion de principio activo que comprende un compuesto 2,5-dihidroxibencenosulfonico y un modulador de los canales de k+.
EP3556401A1 (en) 2005-05-27 2019-10-23 The University of North Carolina at Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
ES2958410T3 (es) 2009-08-21 2024-02-08 Novan Inc Geles tópicos
EP2467173B8 (en) 2009-08-21 2019-06-19 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
WO2012118829A2 (en) 2011-02-28 2012-09-07 Novan, Inc. Tertiary s-nitrosothiol-modified nitricoxide-releasing xerogels and methods of using the same
CN109678764A (zh) * 2018-12-05 2019-04-26 湖北广辰药业有限公司 一种羟苯双磺酸及其钙盐和制备方法
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3681503A (en) * 1970-04-17 1972-08-01 Om Lab Sa Method for combating disturbances of the lipid content of the blood
US4252821A (en) * 1979-12-07 1981-02-24 Laboratoires Om Societe Anonyme Method for treating ulcers
FR2511598A1 (fr) * 1981-08-24 1983-02-25 Gauri Kailash Produit pharmaceutique contenant une substance activant la circulation sanguine, en combinaison avec un concentrat de dialyse de sang de veau deproteine
WO1997037647A1 (fr) * 1996-04-03 1997-10-16 Laboratorios Del Dr. Esteve, S.A. Utilisation des derives 2,5-dihydroxybenzenesulfoniques pour la fabrication de medicaments destines a la normalisation de la fonction endotheliale, pour le traitement de la dysfonction sexuelle et des complications vasculaires du diabete, ainsi que des troubles vasculaires d'origine endotheliale
WO1998029103A2 (en) * 1996-12-30 1998-07-09 Biogal Gyógyszergyár Rt Use of calcium dobesilate for the manufacture of a medicament for the treatment of embryonic retardation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513007A (en) * 1983-05-03 1985-04-23 Laboratoires Om Sa Method for treating heart disease
RU1776408C (ru) * 1990-08-13 1992-11-23 Одесский Медицинский Институт Им.Н.И.Пирогова Способ лечени гломерулонефрита
US6403643B1 (en) * 1997-04-03 2002-06-11 Laboratories Del Dr. Esteve, S.A. Use of 2,5-dihydroxybenzenesulfonic derivatives for the normalization of endothelial function
US5994363A (en) * 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3681503A (en) * 1970-04-17 1972-08-01 Om Lab Sa Method for combating disturbances of the lipid content of the blood
US4252821A (en) * 1979-12-07 1981-02-24 Laboratoires Om Societe Anonyme Method for treating ulcers
FR2511598A1 (fr) * 1981-08-24 1983-02-25 Gauri Kailash Produit pharmaceutique contenant une substance activant la circulation sanguine, en combinaison avec un concentrat de dialyse de sang de veau deproteine
WO1997037647A1 (fr) * 1996-04-03 1997-10-16 Laboratorios Del Dr. Esteve, S.A. Utilisation des derives 2,5-dihydroxybenzenesulfoniques pour la fabrication de medicaments destines a la normalisation de la fonction endotheliale, pour le traitement de la dysfonction sexuelle et des complications vasculaires du diabete, ainsi que des troubles vasculaires d'origine endotheliale
WO1998029103A2 (en) * 1996-12-30 1998-07-09 Biogal Gyógyszergyár Rt Use of calcium dobesilate for the manufacture of a medicament for the treatment of embryonic retardation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
World Patents Index [en línea]. Londres (Reino Unido): Derwent Publications, Ltd. [recuperado el 23.08.2002]. Nö acceso 1993-402392 & SU 1776408 A1 (ODESS PIROGOV INST.) 23.11.1992 (resumen) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2311427A1 (es) * 2004-12-30 2009-02-01 Laboratorios Del Dr. Esteve, S.A. Composicion farmaceutica que comprende un compuesto 2,5-dihidroxibencenosulfonico, un modulador de canales de iones potasio y un inhibidor de la fosfodiesterasa tipo 5.

Also Published As

Publication number Publication date
JP2005501031A (ja) 2005-01-13
US20070197543A1 (en) 2007-08-23
AR036124A1 (es) 2004-08-11
MXPA04000007A (es) 2004-05-21
US20040143010A1 (en) 2004-07-22
HUP0400924A2 (hu) 2004-07-28
EP1413332B1 (en) 2008-12-31
ES2180446B1 (es) 2004-01-16
WO2003004097A1 (es) 2003-01-16
ES2318023T3 (es) 2009-05-01
CA2453572A1 (en) 2003-01-16
PL367766A1 (en) 2005-03-07
HUP0400924A3 (en) 2007-11-28
NO20040007L (no) 2004-02-23
ATE419012T1 (de) 2009-01-15
DE60230629D1 (de) 2009-02-12
BR0211315A (pt) 2004-09-28
EP1413332A1 (en) 2004-04-28

Similar Documents

Publication Publication Date Title
ES2180446A1 (es) Empleo de derivados de acidos 2,5-dihidroxibencenosulfonicos en la elaboracion de un medicamento para potenciar el efecto de otros farmacos en el tratamiento de la disfuncion erectil.
CY1105579T1 (el) Kαρβαμιδο - υποκατεστημενες πυραζολοπυριδινες
GT200000168A (es) Compuestos farmaceuticamente activos.
EA200700892A1 (ru) Липосомная композиция, содержащая активное вещество для релаксации гладкой мускулатуры, получение этой композиции и ее терапевтическое применение
GT200000170A (es) Agentes terapeuticos.
NO20076219L (no) Farmasoytisk formulering med apomorfin for bukkal administrering
BRPI0510862A (pt) medicamento para tratar disfunção sexual em um paciente, medicamento para tratar disfunção erétil em um paciente, medicamento para diminuir os efeitos colaterais associados com os agentes terapêuticos para tratar a disfunção sexual em um paciente, método para fabricação de um medicamento para tratamento da disfunção sexual de um paciente responsivo marginalmente ao inibidor de pde5, e uso do peptìdeo ac-nle-ciclo (-asp-his-d-phe-arg-trp-lys) -0h na perparação de um medicamento
PT828728E (pt) Di-hidrobenzofuranos de fenilo
MY133995A (en) 6-phenylpyrrolopyrimidinedione derivatives
Gudmundsdóttir et al. Sildenafil potentiates nitric oxide mediated inhibition of human platelet aggregation
Wallis The pharmacology of sildenafil, a novel and selective inhibitor of phosphodiesterase (PDE) type 5
DK0828727T3 (da) Cyclohexyldihydrobenzofuraner
ES2462553A1 (es) Composición para mejora del bienestar sexual
WO2001089543A3 (en) Use of proanthocyanidins as an active ingredient of a stimulator and l-arginine or its salts as a source of nitric oxide to relieve symptoms of erectile dysfuntion
BR0215904A (pt) Métodos e composições para prover glutamina
WO2001080860A3 (en) Daily treatment for erectile dysfunction using a pde5 inhibitor
MCAULEY et al. Intracavernosal sildenafil facilitates penile erection independent of the nitric oxide pathway
Grosser et al. A Common Pathway for Nitric Oxide Release from NO–Aspirin and Glyceryl Trinitrate
Aydin et al. Effects of sildenafil citrate, acetylcholine, and sodium nitroprusside on the relaxation of rabbit cavernosal tissue in vitro
JP2004505897A (ja) 特に性機能障害を抑えるための薬剤
PT1259229E (pt) Utilizacao de benzotieno-[2,3-d]-pirimidinas com uma accao inibidora da pde v no tratamento do disfuncao erectil
AR042153A1 (es) Uso de los compuestos 2,5- dihidroxibencenosulfonicos para la fabricacion de un medicamento
ES2285865T3 (es) Utilizacion de una combinacion de una purina y un agente donador de monoxido de nitrogeno para prevenir o tratar disfunciones sexuales.
BRPI0410878A (pt) derivados de benzotiazol e seus usos no tratamento de doenças relacionadas com o receptor a2a da adenosina
Bernardeau et al. Nitric oxide in rheumatology

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20030201

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2180446B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20180807